Russell Hirsch, MD, PhD
Director, Prospect Ventures
Russell Hirsch is a managing director at Prospect Venture Partners, a leading life sciences venture capital firm. Prior to co-founding Prospect Venture Partners II and III, he served as a venture partner and a general partner at Mayfield Fund, where he was a member of the health care technology group. While at Mayfield, he was responsible for the incubation of Intuitive Surgical Devices and participated in the incubation of Millennium Pharmaceuticals. Prior to that, he conducted biomedical research at the University of California, San Francisco, focusing on hepatitis B viral replication. Russell previously served as vice chairman of the board of Interplast and on the Genetics Advisory Council of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. He holds MD and PhD degrees in biochemistry from the University of California, San Francisco and a BA in chemistry from the University of Chicago.
Director, Corning Incorporated
Sarah Burns has been Division Controller Advanced Optics, Corning Specialty Materials since 2017. In this role, she is responsible for all financial processes for Advanced Optics and providing financial guidance and oversight. Sarah joined Corning in 1996 and has held finance leadership positions in Corporate Finance, Corning Display Technologies in Japan and Advanced Optics. Sarah holds a Master of Business Administration degree from the Wharton Business School in University of Pennsylvania.
After earning a SM from the Harvard/MIT Health Sciences and Technology program, Tom joined Siemens where he ran the global MRI business. He has also served as the CEO of the global medical operations of Carl Zeiss, the CEO of Analogic Corporation, and Chairman and CEO of LightLab Imaging, a start-up he helped to establish and sell. Tom re-joined Siemens in 2002 eventually serving as a member of the global operating board of Siemens Healthcare and the CEO of Customer Solutions Division, with 26,000 employees in over 130 countries. In April 2013, Tom started GreyBird Ventures, a consultancy and investment firm.
Board of Directors
Director, Hendale Capital
Henry Lee is the Founder and Managing Partner of Hendale Fund, a growth equity oriented fund which invests in promising scalable platform companies globally. Henry has experience investing across Asian, European, and US regions and has been Chief Investment Officer for a number of large family office groups. He started his career in NY after graduating from the Wharton School of the University of Pennsylvania and worked with the Bass Brothers investment organization in Texas for many years. He currently resides in Hong Kong and serves on the board of a commercial bank in China and the Hong Kong Cancer Fund.
Director, Third Rock Ventures
Mark Levin has more than 36 years of biotech and pharma experience, including 25 years building and operating leading biotech companies. In 2007, he co-founded Third Rock Ventures, where he focuses on the formation, development, and business strategy of its portfolio companies, serving as CEO during their first 12-18 months post-launch. Previously, he co-founded Mayfield Fund’s life sciences effort and was founding CEO and/or board member of its Tularik, Cell Genesys/Abgenix, Focal, Stem Cells, and Millennium Pharmaceuticals companies for 15 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an MS degree in chemical and biochemical engineering from Washington University and is a member of the National Academy of Engineering and the Friends of Personalized Medicine. He is co-founder of upSTART, a Cambridge, Mass., after-school program designed to help aspiring young entrepreneurs run their own businesses.
Eman Namati, PhD
President & CEO
Eman Namati is President and CEO of NinePoint Medical. Eman joined NinePoint during its inception in 2010 as a technical co-founder and most recently served as the Vice President of Research and Development. He has successfully overseen the development of highly complex imaging systems and single-use devices from concept through commercialization, including translation of the original academic prototype into the NvisionVLE® platform. Prior to joining NinePoint, Eman was a post-doctoral research fellow at Massachusetts General Hospital and Harvard Medical School working with Professors Guillermo Tearney, M.D., Ph.D., and Brett Bouma, Ph.D. on the development of the OCT technology that was licensed to NinePoint. He has authored and co-authored over 50 scientific publications, abstracts and book chapters in the fields of signal processing, computed tomography, multi-modal imaging and biomedical optics. Dr. Namati holds a Ph.D. in Biomedical Engineering and a double undergraduate degree in Engineering (BE) and Science (BSc) from Flinders University, Australia.
Eric Swanson brings more than 30 years of technical and operational experience to his position on NinePoint’s board of directors. He is a founding board member of both Acacia Communications and HiveFire Incorporated; an MIT research affiliate; a consultant for Draper Laboratory; and an advisor to high-tech startup companies in a wide range of technologies including biomedical imaging, optics, telecommunications, and Web technologies. Previously, Eric co-founded and was chief scientist and general manager at Sycamore Networks (public NASDAQ), co-founder and chief technology officer of LightLab Imaging (acquired by St. Jude Medical), and co-founder of Advanced Ophthalmic Devices (acquired by Carl Zeiss). Prior to that, he was an R&D group leader at MIT Lincoln Laboratory. Eric has authored more than 200 technical papers and conference presentations, holds numerous U.S. and foreign patents, and is a fellow of the OSA and senior member of the IEEE. He holds a BS degree in electrical engineering from UMass Amherst and an MS degree in electrical engineering from MIT.
Christopher von Jako, PhD
Christopher von Jako brings extensive leadership and experience in the global medical device market with a specific expertise in image guided technologies. He has spent over 20 years focusing on the development and commercialization of image-guided techniques to improve patient experience and outcomes. Most recently, Chris was the President and CEO of NeuroTherm, a medical device company that develops, manufactures, and markets state-of-the-art image-guided solutions for pain management. He successfully executed the divesture of NeuroTherm with his team in August 2014 to St. Jude Medical. Prior to that, Chris was the President of ActiViews, a privately held medical device company, which developed and marketed minimally invasive tools for Interventional Radiology. Prior to this, he worked in senior management positions at Integra LifeSciences, Covidien, Medtronic, and Radionics. Chris holds a PhD in Biomedical Sciences from the University of Pécs Medical School, a MS in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology, and a double BS degree in Physics and Mathematics from Bates College.